0.2 C
New York
Friday, December 2, 2022

There’s No Getting Around Novartis AG (NYSE: NVS) Success

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Novartis AG (NVS) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.23, or -0.28%, to $80.5. Volume reached 30,658 shares, with price reaching a high of $79.58 and a low of $79.58. Yahoo Finance discussed the stock recently as it posted Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report


Stocks Info

NVS belongs to the Healthcare sector of the NYSE while operating in the Drug Manufacturers – General industry. At the end of the last regular session, the stock closed at $79.58 and fluctuated between $80.13 as its day high and $79.35 as its day low. The current market capitalization of Novartis AG is $191.70B. A total of 1.87 million shares were traded on the day, compared to an average of 2.13M shares.


Paying dividends generates immediate cash flow for investors and indicates a positive outlook for the company. Novartis AG pays an annual dividend of $3.33, resulting in a dividend yield of 4.18%, and it has a price to earnings (P/E) ratio of 7.80. NVS’s most recent ex-dividend date was 03/08/2022 when it declared a $3.3252497 quarterly dividend that was paid in cash on 03/17/2022. Previously, the company paid the dividend on 03/15/2021 with an ex-dividend date of 03/04/2021. The dividend was $3.1990725 per share in cash.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for NVS in the last 3 months, the mean price target is $93.28 with high estimates of $110.49 and low estimates of $77.73. In terms of 52-week highs and lows, NVS has a high of $94.26 and a low of $79.09.

As of this writing, NVS has an earnings estimate of $1.57 per share for the current quarter. EPS was calculated based on a consensus of 2 estimates, with a high estimate of $1.59 per share and a lower estimate of $1.55. The company reported an EPS of $1.56 in the last quarter, which was 3.31% higher than expectations of $1.51.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 26 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for NVS is Sell with a score of 3.57. A total of 7 analysts rated the stock as Buy while 2 rated it as Overweight while 13 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 4 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles

Receive Best Stock To Trade Before The Opening Bell



100% Free. Stop Anytime. No Spam



The 5 Best Inflation Stocks for 2022




The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.